Oncology and COVID-19 Pandemic Era-Impact on Medical Oncology Care
In 2019 later, the coronavirus disease 2019(COVID-19)pandemic have killed more than 1 million people worldwide. SARS-CoV2 cause severe pneumonia, the mortality is higher in cancer patients. Moreover, most of cancer patients are elderly and have other co-morbidities which are risk factors of COVID-19. It is still unclear that the relationship between anticancer treatments and COVID-19 are risk factors. Also, the fewer cancer diagnosis for cancer has suggested. The delay of cancer diagnosis will lead to presentation at more advanced stages and poor outcomes. Balancing the value of anticancer treatments with competing risks in COVID-19 pandemic is very difficult. The priorities for cancer care during COVID-19 pandemic affect cancer treatment decisions. However, anticancer treatments have the potential to cure should not be delayed. When treatment has been started, we need to consider the local healthcare system to triage the symptoms that is difficult to distinguish between COVID-19 and side effect of treatment, for example, febrile neutropenia and drug-induced pneumonitis. To continue cancer treatment, education of infection prevention and protection, not only for medical staff but also for patient, are very important.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Gan to kagaku ryoho. Cancer & chemotherapy - 47(2020), 12 vom: 25. Dez., Seite 1662-1667 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Koyama, Taiji [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.12.2020 Date Revised 22.12.2020 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM319078175 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319078175 | ||
| 003 | DE-627 | ||
| 005 | 20231225170707.0 | ||
| 007 | tu | ||
| 008 | 231225s2020 xx ||||| 00| ||jpn c | ||
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM319078175 | ||
| 035 | |a (NLM)33342978 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Koyama, Taiji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oncology and COVID-19 Pandemic Era-Impact on Medical Oncology Care |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2020 | ||
| 500 | |a Date Revised 22.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In 2019 later, the coronavirus disease 2019(COVID-19)pandemic have killed more than 1 million people worldwide. SARS-CoV2 cause severe pneumonia, the mortality is higher in cancer patients. Moreover, most of cancer patients are elderly and have other co-morbidities which are risk factors of COVID-19. It is still unclear that the relationship between anticancer treatments and COVID-19 are risk factors. Also, the fewer cancer diagnosis for cancer has suggested. The delay of cancer diagnosis will lead to presentation at more advanced stages and poor outcomes. Balancing the value of anticancer treatments with competing risks in COVID-19 pandemic is very difficult. The priorities for cancer care during COVID-19 pandemic affect cancer treatment decisions. However, anticancer treatments have the potential to cure should not be delayed. When treatment has been started, we need to consider the local healthcare system to triage the symptoms that is difficult to distinguish between COVID-19 and side effect of treatment, for example, febrile neutropenia and drug-induced pneumonitis. To continue cancer treatment, education of infection prevention and protection, not only for medical staff but also for patient, are very important | ||
| 650 | 4 | |a Journal Article | |
| 773 | 0 | 8 | |i Enthalten in |t Gan to kagaku ryoho. Cancer & chemotherapy |d 1993 |g 47(2020), 12 vom: 25. Dez., Seite 1662-1667 |w (DE-627)NLM012601861 |x 0385-0684 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2020 |g number:12 |g day:25 |g month:12 |g pages:1662-1667 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2020 |e 12 |b 25 |c 12 |h 1662-1667 | ||